Quick Answer
ARS Pharmaceuticals, Inc. reported Diluted EPS of $1.74 per share (loss) for fiscal year 2025.
ARS Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.74 | -2275.0% |
| 2024 | $0.08 | +114.0% |
| 2023 | -$0.57 | +34.5% |
| 2022 | -$0.87 | -24.3% |
| 2021 | -$0.70 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.52 | -160.0% | -13.0% |
| June 30, 2025 | -$0.46 | -253.8% | -31.4% |
| March 31, 2025 | -$0.35 | -218.2% | -75.0% |
| September 30, 2024 | -$0.20 | -25.0% | -53.8% |
| June 30, 2024 | -$0.13 | +27.8% | -18.2% |
| March 31, 2024 | -$0.11 | +31.2% | +31.2% |
| September 30, 2023 | -$0.16 | +23.8% | +11.1% |
| June 30, 2023 | -$0.18 | +14.3% | -12.5% |
- ARS Pharmaceuticals, Inc. showed a decrease of -2275.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, ARS Pharmaceuticals, Inc.’s diluted eps has declined by 148.6% (from $0.70 per share (loss) to $1.74 per share (loss)).
- The most recent figure is from ARS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: